In this episode we question the conclusions of the phase II trial "Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma", review the long-term overall survival results from PALOMA-3, discuss Dr. Gyawali et al.'s paper on the need for transparency in reporting harms from cancer drugs, and interview Dr. Talal Hilal from the Scottsdale Mayo Clinic on his advice for trainees.

Nab-paclitaxel and gemcitabine: doi.org/10.1001/jamaoncol.2018.3277

Palbociclib and fulvestrant: doi.org/10.1056/NEJMoa1810527

Reporting harms: doi.org/10.1136/bmj.k4383